India’s healthcare sector is confronting a deepening medical inflation crisis that threatens to push millions of households into catastrophic expenditure and debt. Reports in May 2026 highlight that while the government’s Economic Survey for 2025-26 reported health inflation slowing to 3 percent, private industry surveys such as Aon’s Global Medical Trends Rate 2026 place actual medical inflation at 12 to 13 percent — a fourfold discrepancy that reveals a fundamental tension between official data and ground-level reality.
The implications of this divergence are profound. India has one of the highest rates of out-of-pocket expenditure (OOPE) in healthcare globally, with approximately 61 percent of hospitalizations occurring in private hospitals that are governed by inadequate price regulation. As of 2025, the average OOPE per hospitalization case excluding childbirth stood at Rs. 34,064, with urban private hospitals averaging Rs. 50,508 per case. For the vast majority of Indians whose monthly household income falls below this threshold, a single hospitalization event is economically catastrophic.
💡 Get AI-powered exam prep on your phone!
For UPSC aspirants, this issue is a masterclass in the intersection of public health policy, economic inequality, institutional failure, and constitutional obligations. The right to health, while not explicitly mentioned in the Constitution, has been read into Article 21 (right to life) by the Supreme Court in numerous judgments. Understanding why India’s healthcare market fails, how government schemes like Ayushman Bharat address only part of the problem, and what structural reforms are necessary constitutes core preparation for GS-II and GS-III.
Background and Context: The Structural Roots of Healthcare Inflation
India’s healthcare market is characterized by information asymmetry, regulatory fragmentation, and an overwhelming dependence on private providers. The privatization of healthcare, driven by the state’s retreat from public provisioning since the 1990s, has created a profit-driven ecosystem where prices are determined by market logic rather than social need.
Five Important Key Points
- As of 2025, only 47.4 percent of rural and 44.3 percent of urban households had any form of health insurance coverage, meaning the majority of Indians bear the full cost of medical care from their own savings or through distress financing.
- Private equity investment in Indian healthcare reached 5.5 billion dollars in 2023, reflecting the commodification of healthcare and the entry of profit-maximizing institutional investors who prioritize returns over affordability.
- The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana covers only secondary and tertiary hospitalization for 12 crore poor families with up to Rs. 5 lakh per year, leaving out the “missing middle” — those too wealthy for the scheme but too poor to afford private insurance.
- India’s public health expenditure remains below 2 percent of GDP, compared to an average of over 6 percent in OECD countries, creating chronic underinvestment in primary and secondary public healthcare infrastructure.
- The Clinical Establishments (Registration and Regulation) Act, 2010 mandates price regulation for clinical procedures, but its implementation remains deeply fragmented because healthcare is a State subject under the Concurrent List, and most States have either not adopted or not enforced the Act.
The Price Regulation Gap: Legislative Framework and Its Failures
The Clinical Establishments Act, 2010 was designed to bring private hospitals and clinics within a regulatory framework by requiring registration and mandating adherence to government-determined pricing ranges for procedures. However, the Act has faced chronic non-implementation for several structural reasons.
Since health is a subject on the Concurrent List (Entry 6 of the Concurrent List), both Parliament and State Legislatures have jurisdiction. Many States have enacted their own clinical establishment regulations, creating a patchwork of standards with little national coherence. The Supreme Court in March 2025 urged States to frame guidelines to prevent overcharging, but this advisory remains non-binding. The absence of an independent national pricing regulator for healthcare services — comparable to the National Pharmaceutical Pricing Authority (NPPA) for drugs — means that private hospitals effectively self-regulate their pricing.
The Pharmaceutical Dimension: Drug Price Inflation and the Essential Medicines List
Drug pricing is a separate but related dimension of medical inflation. The National List of Essential Medicines 2022 contains 384 drugs whose prices are capped by the NPPA through a market-based formula. However, the WHO’s Essential Medicines List contains 520 drugs, meaning that several life-saving medicines remain outside price control in India.
The price cap mechanism itself has limitations: it applies at the manufacturer level but does not control retail markups, which can be substantial in private pharmacies and hospital dispensaries. The practice of hospitals maintaining exclusive supply chains and charging substantially above MRP for in-patient medications is widespread and poorly regulated.
Ayushman Bharat and Its Structural Limitations
The Ayushman Bharat scheme represents the most ambitious attempt by the Indian government to address healthcare access. Under PM-JAY, 12 crore poor and vulnerable families are entitled to Rs. 5 lakh in annual coverage for secondary and tertiary hospitalization. The scheme has had genuine success in some States, particularly in reducing the incidence of catastrophic expenditure among its target beneficiaries.
However, the scheme faces significant structural challenges. Claim rejection rates remain high due to documentation requirements, fraud by empaneled hospitals, and delays in reimbursement. The “missing middle” — households above the poverty line but without private insurance — is entirely unserved. More fundamentally, the scheme covers only hospitalization and excludes the largest component of OOPE: outpatient consultation fees, diagnostic tests, and medicines, which constitute 60 to 70 percent of actual healthcare spending.
The Diagnostic Inflation Problem
Rising costs of diagnostic tests — including genomic tests, advanced imaging, and biomarker analyses — represent a growing component of medical inflation. The proliferation of corporate diagnostic chains operating on a high-volume, high-margin model has increased both the availability and the cost of diagnostic services. Physicians, in a system with limited accountability, frequently prescribe unnecessary diagnostics, driving OOPE without improving health outcomes.
The Supreme Court’s observation in March 2025 about the need for guidelines to prevent unnecessary and expensive treatments is relevant here. A national clinical practice guidelines framework, developed by the Indian Council of Medical Research in consultation with specialist bodies, could provide evidence-based standards that limit unnecessary testing and treatment.
Public Sector Strengthening: The Under-Utilized Solution
The most sustainable solution to medical inflation is the strengthening of the public healthcare system. India’s public hospitals, when adequately resourced, provide care at dramatically lower cost: average OOPE in government hospitals was Rs. 6,631 per hospitalization, compared to Rs. 50,508 in private hospitals. This difference reflects the public subsidy that makes care accessible, not inferior quality of care.
However, public hospitals are severely under-resourced: they lack diagnostic equipment, specialist personnel, essential medicines in adequate supply, and modern infrastructure. The Health and Family Welfare Sector received Rs. 1,04,559 crore in the Union Budget 2026, which amounts to only 0.26 percent of GDP — far below the National Health Policy 2017 target of 2.5 percent of GDP by 2025.
Way Forward
India must pursue a multi-pronged strategy to address medical inflation. The Union government should urgently increase public health expenditure to at least 2.5 percent of GDP, prioritizing primary health centers and district hospitals. The NPPA’s mandate should be expanded from pharmaceutical pricing to include commonly performed clinical procedures in private hospitals. A national health technology assessment body should be established to evaluate the cost-effectiveness of emerging diagnostic and therapeutic technologies before they enter common use. Ayushman Bharat should be expanded to cover outpatient care and extended to the missing middle through subsidized contributory insurance. The Essential Medicines List should be updated annually rather than periodically, and the enforcement of price caps should be strengthened through third-party monitoring.
Relevance for UPSC and SSC Examinations
This topic is relevant for UPSC GS-II (Health, Government Policies and Schemes), GS-III (Indian Economy, Infrastructure), and Essay papers (healthcare as a public good). For SSC examinations, it covers General Awareness in Economy and Schemes. Key terms aspirants should remember include Ayushman Bharat PM-JAY, out-of-pocket expenditure, Clinical Establishments Act 2010, National Pharmaceutical Pricing Authority, National Health Policy 2017, and the missing middle in health insurance.